Addendum
Etelcalcetide (secondary hyperparathyroidism) - Addendum to Commission A17-25
Report documents
-
Addendum
Etelcalcetide (secondary hyperparathyroidism) - Addendum to Commission A17-25
Dossier assessment
Indication:
Secondary hyperparathyroidism
Result of dossier assessment:
Study 20120360: neither advantage nor disadvantage proven for etelcalcetide in comparison with cinacalcet
Additional information
Federal Joint Committee (G-BA)
2017-11-17 A G-BA decision was published.
Project details
- Project no.
- A17-53
- Commission
- Commission awarded on 09.10.2017 by the Federal Joint Committee (GBA).
- Report type
- Addendum
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Digestion, metabolism and hormones
- Note
-
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
Connected Projects
-
Dossier assessment
Etelcalcetide (secondary hyperparathyroidism) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed